Exhibit
10.26


 





Addendum
Number 3 of the “Up to USD


150,000.00 Credit Facilites Agreement”


 


“Addendum”


 


of


 


___
October 2020


 


between


  





	NLS
    Pharmaceutics Ltd.	 	 
	Alter
    Postplatz	 	 
	6370
    Stans	 	 
	Switzerland	 	“Borrower”
	 	and	 
	Ronald
    Hafner	 	 
	 	 	“Lender
    1”
	Jürgen
    Bauer	 	 
	 	 	“Lender
    2”
	Peter
    Ödman	 	 
	 	 	“Lender
    3”
	Michael
    Stein	 	 
	 	 	“Lender
    4”
	 	 	 
	 	 	(Lender
    1, Lender 2, Lender 3 and Lender 4
	 	 	the  Lenders
    )
	 	 	(Borrower
    and Lenders each a  Party
	 	 	collectively
    the  Parties )




 


regarding


current
situation and outstanding amount



 






     


    	Addendum	2/3



    

 





WHEREAS


 


		A.	The
                                         Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss
                                         law with its registered seat and principal place of business at Stans (Company Number
                                         CHE-447.067.367). The Company has a share capital of CHF 139’200.00, divided into
                                         6’960’000 registered shares with a nominal value of CHF 0.02 each, which
                                         have been fully paid in.



 


		B.	The
                                         Lenders and the Borrower (formerly NLS Pharma AG) entered into the “Up to USD 150,000.00
                                         Credit Facilities Agreement” dated 31 August 2015, as amended on 16 September 2019
                                         and on 3 February 2020 (“Agreement”). The Lenders agreed to make available
                                         to the Borrower credit facilities in the aggregate amount of USD 150,000.00 (“Total
                                         Credit Facility Amount”).



 


		C.	The
                                         Lenders granted to the Borrower the Total Credit Facility Amount under the Agreement.



 


		D.	According
                                         to section 6.1 of the Agreement, the loans under Total Credit Facility Amount shall bear
                                         regular interest at the rate of 0% per annum, calculated from (and including) the day
                                         of its drawdown to (and including) the Maturity Date (or the date of its earlier repayment).



 


		E.	According
                                         to section 6.2 of the Agreement, default interest rate of 5% per annum shall apply, in
                                         case the Borrower does not make any payment on the due date as foreseen in the Agreement.



 


		F.	The
                                         maturity date for the repayment of the Total Credit Facility Amount together with the
                                         accrued interest was set at 30 September 2020 (“Maturity Date”).



  


NOW,
THEREFORE, the Parties agree as follows:


 


Any
capitalized terms, if not defined otherwise in this Addendum, shall have the meaning as set forth in the Agreement.


 


		1.	Open
                                         Amount



 


The
Parties hereby confirm that the Total Credit Facility Amount has not been repaid to the Lenders by the Borrower.


 


		2.	Extension
                                         Maturity Date



 


The
Maturity Date as set forth in section 5 of the Agreement shall be extended from 30 September 2020 to 31 December 2020.


 


		3.	Governing
                                         Law and Jurisdiction



 


This
Addendum shall be governed by and construed in accordance with the substantive laws of Switzerland, without reference to principles
of conflict of laws or choice of laws.


 


All
disputes arising out of or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment
and termination, shall be resolved by the ordinary courts in Stans (NW), Switzerland.


 


[Signature
page to follow]


 




     


    	Addendum	3/3



    

  


Borrower 


 


NLS
Pharmaceutics Ltd.


  





	/s/
Ronald Hafner	 	/s/ Alexander Zwyer
	Ronald
    Hafner	 	Alexander
    Zwyer
	Chairman
    of the Board	 	Chief
    Executive Officer
	 	 	 
	 	 	 
	Lenders	 	 
	 	 	 
	/s/ Ronald
    Hafner	 	/s/ Jürgen
    Bauer
	Ronald
    Hafner	 	Jürgen
    Bauer
	 	 	 
	/s/ Peter
    Ödman	 	/s/ Michael
    Stein
	Peter
    Ödman	 	Michael
    Stein